Sonoma Pharmaceuticals Announces Relaunch of Prescription Dermatology and Eye Care Product Lines in the United States
Sonoma Pharmaceuticals (Nasdaq:SNOA) announced the relaunch of its prescription dermatology and eye care product lines in the United States. The company will now directly sell its Microcyn technology-based products, which were previously distributed through a third party. The product lineup includes prescription-strength items like Acuicyn, Epicyn, Levicyn, and Celacyn, along with over-the-counter options Lasercyn Dermal Spray and Gel. These hypochlorous acid-based products will be available from December 9, 2024, with pre-ordering options available.
Sonoma Pharmaceuticals (Nasdaq:SNOA) ha annunciato il rilancio delle sue linee di prodotti dermatologici e per la cura degli occhi negli Stati Uniti. L'azienda sarà ora in grado di vendere direttamente i suoi prodotti a base di tecnologia Microcyn, precedentemente distribuiti tramite un terzo. La gamma di prodotti include articoli con prescrizione come Acuicyn, Epicyn, Levicyn, e Celacyn, insieme a opzioni da banco come Lasercyn Dermal Spray e Gel. Questi prodotti a base di acido ipocloroso saranno disponibili dal 9 dicembre 2024, con opzioni di pre-ordine disponibili.
Sonoma Pharmaceuticals (Nasdaq:SNOA) anunció el relanzamiento de sus líneas de productos de dermatología y cuidado ocular en los Estados Unidos. La compañía ahora venderá directamente sus productos basados en tecnología Microcyn, que anteriormente se distribuían a través de un tercero. La línea de productos incluye artículos con receta como Acuicyn, Epicyn, Levicyn, y Celacyn, junto con opciones de venta libre como Lasercyn Spray y Gel dérmico. Estos productos a base de ácido hipocloroso estarán disponibles a partir del 9 de diciembre de 2024, con opciones de pre-pedido disponibles.
소노마 제약(Sonoma Pharmaceuticals) (Nasdaq:SNOA)는 미국에서의 처방 피부과 및 안과 제품 라인의 재출시를 발표했습니다. 이 회사는 이제 이전에 제3자를 통해 유통되던 마이크로신 기술 기반 제품을 직접 판매할 것입니다. 제품 라인에는 처방약인 Acuicyn, Epicyn, Levicyn, Celacyn 및 일반 의약품인 Lasercyn 피부 스프레이와 젤이 포함됩니다. 이들 산소산 기반 제품은 2024년 12월 9일부터 구매 가능하며, 사전 주문 옵션이 제공됩니다.
Sonoma Pharmaceuticals (Nasdaq:SNOA) a annoncé le relancement de ses lignes de produits dermatologiques et de soins oculaires aux États-Unis. La société vendra désormais directement ses produits à base de technologie Microcyn, qui étaient auparavant distribués par un tiers. La gamme de produits comprend des articles sur ordonnance tels que Acuicyn, Epicyn, Levicyn, et Celacyn, ainsi que des options en vente libre comme Lasercyn spray dermal et gel. Ces produits à base d'acide hypochloreux seront disponibles à partir du 9 décembre 2024, avec des options de précommande disponibles.
Sonoma Pharmaceuticals (Nasdaq:SNOA) hat die Wiederveröffentlichung seiner verschreibungspflichtigen dermatologischen und augenärztlichen Produktlinien in den Vereinigten Staaten angekündigt. Das Unternehmen wird nun seine auf Microcyn-Technologie basierenden Produkte direkt verkaufen, die zuvor über einen Dritten vertrieben wurden. Das Produktangebot umfasst verschreibungspflichtige Artikel wie Acuicyn, Epicyn, Levicyn und Celacyn, sowie rezeptfreie Optionen wie Lasercyn Dermalspray und Gel. Diese Produkte auf Hypochloritbasis werden ab dem 9. Dezember 2024 zur Verfügung stehen, mit Vorbestelloptionen.
- Direct sales model implementation eliminates distributor dependency
- Expansion of product portfolio with both prescription and OTC offerings
- Relaunch of established products with existing physician recognition
- None.
Insights
The relaunch of prescription product lines marks a strategic shift in Sonoma's business model, moving from distributor-based to direct sales. This transition could potentially improve profit margins by eliminating middleman costs. The timing is particularly noteworthy as it includes both prescription and OTC products, creating a comprehensive portfolio targeting multiple market segments.
The reintegration of these established products, particularly in dermatology and eye care, represents a significant revenue opportunity. The direct-to-physician approach could strengthen relationships with healthcare providers and provide better control over pricing and distribution. However, success will heavily depend on Sonoma's ability to effectively manage direct sales operations and maintain existing customer relationships during the transition.
BOULDER, CO / ACCESSWIRE / November 21, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced the relaunch of its prescription dermatology and eye care products lines.
The prescription-strength products include: Acuicyn® Eyelid & Eyelash Hygiene, Epicyn® Facial Cleanser, Levicyn® Dermal Spray, Levicyn® Gel, Levicyn® Spray Gel and Celacyn® Scar Management Gel. In addition, Lasercyn® Dermal Spray and Lasercyn® Gel are available for over-the-counter use. These hypochlorous acid-based products were previously sold through a distributor to physicians, clinics and pharmacies. The products will now be available directly from Sonoma.
"We are excited to bring back these trusted products and expand our direct offerings for dermatology and eye care," said Amy Trombly, CEO of Sonoma. "These prescription products complement our over-the-counter product line in the U.S., allowing health care professionals and their patients multiple options for effective and safe eye care and scar management, as well as freedom from itch, pain and common skin irritations, including relief following ophthalmological and cosmetic procedures. These products are well-known and well-regarded by physicians across the country, and represent the versatile power of our Microcyn technology."
All products will be available December 9, 2024 and can be pre-ordered prior to that date. For more information or to place an order, contact our customer service department at 720-452-9690 or customerservice@sonomapharma.com.
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma's products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact busdev@sonomapharma.com.
Forward-Looking Statements
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "develop," "anticipate," "expect" and "expand," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company's cash needs, fund further development, as well as uncertainties relative to the COVID-19 pandemic and economic development, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals™, Microcyn®, Acuicyn®, Epicyn®, Levicyn®, Celacyn® and Lasercyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.
Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.
ir@sonomapharma.com
Website: www.sonomapharma.com
Follow us on LinkedIn: https://www.linkedin.com/company/sonoma-pharmaceuticals
Follow us on Instagram: https://www.instagram.com/sonomapharma_us/
Follow us on Facebook: https://www.facebook.com/sonomapharma/
SOURCE: Sonoma Pharmaceuticals, Inc.
View the original press release on accesswire.com
FAQ
When will Sonoma Pharmaceuticals (SNOA) relaunch its prescription products in the US?
What products is Sonoma Pharmaceuticals (SNOA) relaunching in December 2024?
How will Sonoma Pharmaceuticals (SNOA) distribute its relaunched products?
